What is the share price of Alembic Pharmaceuticals Ltd (APLLTD) today?
The share price of APLLTD as on 10th July 2025 is ₹977.10. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Alembic Pharmaceuticals Ltd (APLLTD) share?
The past returns of Alembic Pharmaceuticals Ltd (APLLTD) share are- Past 1 week: -1.07%
- Past 1 month: -0.49%
- Past 3 months: 16.28%
- Past 6 months: -3.26%
- Past 1 year: -0.80%
- Past 3 years: 33.31%
- Past 5 years: 3.79%
What are the peers or stocks similar to Alembic Pharmaceuticals Ltd (APLLTD)?
The peers or stocks similar to Alembic Pharmaceuticals Ltd (APLLTD) include:What is the dividend yield % of Alembic Pharmaceuticals Ltd (APLLTD) share?
The current dividend yield of Alembic Pharmaceuticals Ltd (APLLTD) is 1.13.What is the market cap of Alembic Pharmaceuticals Ltd (APLLTD) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Alembic Pharmaceuticals Ltd (APLLTD) is ₹19206.18 Cr as of 10th July 2025.What is the 52 week high and low of Alembic Pharmaceuticals Ltd (APLLTD) share?
The 52-week high of Alembic Pharmaceuticals Ltd (APLLTD) is ₹1303.90 and the 52-week low is ₹725.20.What is the PE and PB ratio of Alembic Pharmaceuticals Ltd (APLLTD) stock?
The P/E (price-to-earnings) ratio of Alembic Pharmaceuticals Ltd (APLLTD) is 32.92. The P/B (price-to-book) ratio is 3.70.Which sector does Alembic Pharmaceuticals Ltd (APLLTD) belong to?
Alembic Pharmaceuticals Ltd (APLLTD) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Alembic Pharmaceuticals Ltd (APLLTD) shares?
You can directly buy Alembic Pharmaceuticals Ltd (APLLTD) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Alembic Pharmaceuticals Ltd
APLLTD Share Price
APLLTD Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
APLLTD Performance & Key Metrics
APLLTD Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
32.92 | 3.70 | 1.13% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
36.59 | 6.40 | 0.79% |
from 11 analysts
Price Upside
Earnings Growth
Rev. Growth
APLLTD Company Profile
Alembic Pharmaceuticals Limited is a pharmaceutical company engaged in developing formulations and active pharmaceutical ingredients (API).
APLLTD Sentiment Analysis
APLLTD Sentiment Analysis
APLLTD Stock Summary · May 2025
Alembic Pharmaceuticals demonstrated robust revenue growth of 17% in Q4 FY'25, driven by strong performance in key segments like gynecology and animal health, despite facing challenges in profitability due to increased tax provisions and declining gross margins. The company is strategically managing inventory levels in anticipation of multiple product launches, while also investing significantly in R&D and new manufacturing facilities to support future growth, particularly in complex products. Internationally, the business thrived, especially in the ex-US market, although pricing pressures in the U.S. segment raised concerns. Looking ahead, management remains optimistic about mid to high teens growth in FY'26, contingent on successful product introductions and market strategies.
APLLTD Stock Growth Drivers
APLLTD Stock Growth Drivers
7Strong Financial Performance
Alembic Pharmaceuticals reported a revenue growth of 17% for Q4 FY'25, reaching Rs. 1,770 crores,
Growth in Key Business Segments
The India business achieved an 8% growth in Q4, with a topline of Rs. 545
APLLTD Stock Challenges
APLLTD Stock Challenges
5Declining Earnings and Profitability
Alembic Pharmaceuticals has reported a decrease in earnings per share (EPS) for the current quarter
Increased Borrowings and Working Capital Concerns
The company has seen a rise in short-term borrowings due to increased working capital requirements.
APLLTD Forecast
APLLTD Forecasts
Price
Revenue
Earnings
APLLTD Share Price Forecast
APLLTD Share Price Forecast
All values in ₹
All values in ₹
APLLTD Company Revenue Forecast
APLLTD Company Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
APLLTD Stock EPS (Earnings Per Share) Forecast
APLLTD Stock EPS (Earnings Per Share) Forecast
All values in ₹
All values in ₹
APLLTD
APLLTD
Income
Balance Sheet
Cash Flow
APLLTD Income Statement
APLLTD Income Statement
Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 3,107.17 | 3,137.84 | 3,944.06 | 4,610.69 | 5,480.42 | 5,361.53 | 5,655.36 | 6,256.94 | 6,728.37 | 6,729.03 | ||||||||||
Raw Materials | 928.05 | 927.62 | 1,084.97 | 1,249.98 | 1,451.27 | 1,489.61 | 1,630.17 | 1,857.92 | 2,083.13 | 5,664.50 | ||||||||||
Power & Fuel Cost | 64.20 | 70.35 | 88.86 | 102.40 | 118.72 | 120.84 | 151.54 | 173.37 | 179.69 | |||||||||||
Employee Cost | 558.83 | 622.81 | 746.69 | 906.44 | 1,051.17 | 1,133.00 | 1,169.13 | 1,446.29 | 1,562.34 | |||||||||||
Selling & Administrative Expenses | 791.13 | 700.51 | 961.11 | 913.65 | 1,104.03 | 1,354.87 | 1,474.00 | 1,543.70 | 1,650.86 | |||||||||||
Operating & Other expenses | 147.67 | 166.42 | 179.47 | 253.92 | 187.65 | 333.31 | 550.33 | 274.97 | 187.82 | |||||||||||
EBITDA | 617.29 | 650.13 | 882.96 | 1,184.30 | 1,567.58 | 929.90 | 680.19 | 960.69 | 1,064.53 | 1,064.53 | ||||||||||
Depreciation/Amortization | 82.97 | 105.46 | 115.23 | 157.32 | 183.48 | 286.78 | 275.43 | 272.67 | 278.58 | 278.58 | ||||||||||
PBIT | 534.32 | 544.67 | 767.73 | 1,026.98 | 1,384.10 | 643.12 | 404.76 | 688.02 | 785.95 | 785.95 | ||||||||||
Interest & Other Items | 5.23 | 3.40 | 18.41 | 27.16 | 16.02 | 17.73 | 50.17 | 56.19 | 78.77 | 78.77 | ||||||||||
PBT | 529.09 | 541.27 | 749.32 | 999.82 | 1,368.08 | 625.39 | 354.59 | 631.83 | 707.18 | 707.18 | ||||||||||
Taxes & Other Items | 125.93 | 128.64 | 164.95 | 171.00 | 221.58 | 104.45 | 12.60 | 16.01 | 123.76 | 123.75 | ||||||||||
Net Income | 403.16 | 412.63 | 584.37 | 828.82 | 1,146.50 | 520.94 | 341.99 | 615.82 | 583.42 | 583.43 | ||||||||||
EPS | 21.39 | 21.89 | 31.00 | 43.97 | 59.55 | 26.50 | 17.40 | 31.33 | 29.68 | 29.68 | ||||||||||
DPS | 4.00 | 4.00 | 5.50 | 10.00 | 14.00 | 10.00 | 8.00 | 11.00 | 11.00 | 11.00 | ||||||||||
Payout ratio | 0.19 | 0.18 | 0.18 | 0.23 | 0.24 | 0.38 | 0.46 | 0.35 | 0.37 | 0.37 |
APLLTD Company Updates
APLLTD Stock Peers
APLLTD Past Performance & Peer Comparison
APLLTD Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Alembic Pharmaceuticals Ltd | 32.92 | 3.70 | 1.13% |
Sun Pharmaceutical Industries Ltd | 36.50 | 5.50 | 0.96% |
Cipla Ltd | 22.64 | 3.82 | 1.08% |
Torrent Pharmaceuticals Ltd | 59.13 | 14.89 | 0.18% |
APLLTD Stock Price Comparison
Compare APLLTD with any stock or ETFAPLLTD Holdings
APLLTD Shareholdings
APLLTD Promoter Holdings Trend
APLLTD Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
APLLTD Institutional Holdings Trend
APLLTD Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
APLLTD Shareholding Pattern
APLLTD Shareholding Pattern
APLLTD Shareholding History
APLLTD Shareholding History
Mutual Funds Invested in APLLTD
Mutual Funds Invested in APLLTD
No mutual funds holding trends are available
Top 5 Mutual Funds holding Alembic Pharmaceuticals Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.8742% | Percentage of the fund’s portfolio invested in the stock 2.01% | Change in the portfolio weight of the stock over the last 3 months 0.24% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 49/82 (+2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.6264% | Percentage of the fund’s portfolio invested in the stock 1.61% | Change in the portfolio weight of the stock over the last 3 months 0.22% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 29/60 (+9) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.8279% | Percentage of the fund’s portfolio invested in the stock 0.94% | Change in the portfolio weight of the stock over the last 3 months 0.15% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 60/83 (-5) |
Compare 3-month MF holding change on Screener
smallcases containing APLLTD stock
smallcases containing APLLTD stock
Looks like this stock is not in any smallcase yet.
APLLTD Events
APLLTD Events
APLLTD Dividend Trend
Current dividend yield is 1.13%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹11.26 every year
Dividends
Corp. Actions
Announcements
Legal Orders
APLLTD Dividend Trend
Current dividend yield is 1.13%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹11.26 every year
APLLTD Upcoming Dividends
APLLTD Upcoming Dividends
Cash Dividend
Ex DateEx DateJul 29, 2025
Dividend/Share
₹11.00
Ex DateEx Date
Jul 29, 2025
APLLTD Past Dividends
APLLTD Past Dividends
Cash Dividend
Ex DateEx DateJul 15, 2024
Dividend/Share
₹11.00
Ex DateEx Date
Jul 15, 2024
Cash Dividend
Ex DateEx DateJul 28, 2023
Dividend/Share
₹8.00
Ex DateEx Date
Jul 28, 2023
Cash Dividend
Ex DateEx DateAug 17, 2022
Dividend/Share
₹10.00
Ex DateEx Date
Aug 17, 2022
Cash Dividend
Ex DateEx DateJul 19, 2021
Dividend/Share
₹14.00
Ex DateEx Date
Jul 19, 2021
Cash Dividend
Ex DateEx DateMar 16, 2020
Dividend/Share
₹7.00
Ex DateEx Date
Mar 16, 2020
APLLTD Stock News & Opinions
APLLTD Stock News & Opinions
Krishnan is a seasoned finance professional with over 22 years of experience across the pharmaceuticals, life sciences, telecom, and social sectors. He is a qualified Chartered Accountant (CA), Company Secretary (CS), and Cost and Management Accountant (CMA). Prior to joining Alembic, Krishnan served as Vice President and CFO at Syngene Scientific Solutions, a subsidiary of Syngene International, since May 2020. During his tenure, he played a crucial role in driving strategy, business finance, mergers & acquisitions, governance and risk management. He has also held key leadership positions at Vodafone and Tata Trusts. Krishnan brings with him expertise in business finance, M&A, scalable systems implementation, and governance frameworks, along with managing diverse finance teams. Meanwhile, the company also informed that R. K. Baheti, Director ' Finance and the current CFO, has relinquished his role as CFO effective 7 July 2025. However, he will continue to serve on the board as an executive director, in line with the terms of his appointment. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA. The company's consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.37% to Rs 1,004.20 on the BSE. Powered by Capital Market - Live
Utility Therapeutics is involved in the development and approval of two brand pharmaceutical products for the treatment of urinary tract infections (UTI). The first product 'Pivya' is an FDA approved product to treat uncomplicated UTIs in the US market. The second product 'MEC' is in development for the treatment of complicated UTIs in the US market. As a product development company they have minimal turnover in last 3 years. Alembic Pharma stated that the acquisition has been made to market the US FDA approved product and under-development product owned by the Utility in USA. The acquisition cost involves a cash component plus profit share out of future profits. The total amount payable is approximately $12 million. The payout would happen in staggered manner over period of time, depending on milestones achieved. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA. The company's consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24. The scrip advanced 0.95% to currently trade at Rs 999.05 on the BSE. Powered by Capital Market - Live
Alembic Pharmaceuticals Inc., wholly owned subsidiary of Alembic Pharmaceuticals has acquired Utility Therapeutics for a consideration of $12 million in staggered manner over period of time, depending on milestones achieved. Utility Therapeutics is involved in the development and approval of two brand pharmaceutical products for the treatment of urinary tract infections (UTI). -'Pivya' is an FDA approved product to treat uncomplicated UTIs in the US market. -'MEC' is a product in development for treatment of the complicated UTIs in the US market. As a product development company they have minimal turnover in last 3 years.Powered by Capital Market - Live
Jyoti CNC Automation Ltd, Raymond Ltd, TBO Tek Ltd, Raymond Lifestyle Ltd are among the other stocks to see a surge in volumes on NSE today, 30 June 2025.Alembic Pharmaceuticals Ltd recorded volume of 128.6 lakh shares by 14:14 IST on NSE, a 124.17 times surge over two-week average daily volume of 1.04 lakh shares. The stock gained 9.79% to Rs.1,063.80. Volumes stood at 1.17 lakh shares in the last session.Jyoti CNC Automation Ltd registered volume of 177.53 lakh shares by 14:14 IST on NSE, a 74.1 fold spurt over two-week average daily volume of 2.40 lakh shares. The stock slipped 5.83% to Rs.1,060.00. Volumes stood at 1.17 lakh shares in the last session.Raymond Ltd clocked volume of 91.06 lakh shares by 14:14 IST on NSE, a 21.3 times surge over two-week average daily volume of 4.28 lakh shares. The stock gained 14.44% to Rs.714.50. Volumes stood at 12.85 lakh shares in the last session.TBO Tek Ltd recorded volume of 10.93 lakh shares by 14:14 IST on NSE, a 12.52 times surge over two-week average daily volume of 87327 shares. The stock gained 0.56% to Rs.1,399.90. Volumes stood at 2.02 lakh shares in the last session.Raymond Lifestyle Ltd saw volume of 38.22 lakh shares by 14:14 IST on NSE, a 9.57 fold spurt over two-week average daily volume of 3.99 lakh shares. The stock increased 12.71% to Rs.1,377.60. Volumes stood at 12.04 lakh shares in the last session.Powered by Capital Market - Live
Jindal Worldwide Ltd, RattanIndia Power Ltd, AAVAS Financiers Ltd and Force Motors Ltd are among the other gainers in the BSE's 'A' group today, 30 June 2025.Alembic Pharmaceuticals Ltd surged 13.49% to Rs 1103 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 4.68 lakh shares were traded on the counter so far as against the average daily volumes of 5051 shares in the past one month. Jindal Worldwide Ltd soared 10.36% to Rs 61.58. The stock was the second biggest gainer in 'A' group. On the BSE, 4.29 lakh shares were traded on the counter so far as against the average daily volumes of 31183 shares in the past one month. RattanIndia Power Ltd spiked 6.94% to Rs 15.4. The stock was the third biggest gainer in 'A' group. On the BSE, 374.19 lakh shares were traded on the counter so far as against the average daily volumes of 193.98 lakh shares in the past one month. AAVAS Financiers Ltd spurt 6.20% to Rs 2115.45. The stock was the fourth biggest gainer in 'A' group. On the BSE, 33883 shares were traded on the counter so far as against the average daily volumes of 7113 shares in the past one month. Force Motors Ltd advanced 6.06% to Rs 15377.15. The stock was the fifth biggest gainer in 'A' group. On the BSE, 8028 shares were traded on the counter so far as against the average daily volumes of 12061 shares in the past one month. Powered by Capital Market - Live
The domestic equity benchmarks traded with modest losses in morning trade, weighed down by a mix of global and domestic factors. India's recent forex data revealed a decline in its reserves. Meanwhile, the Israel-Iran truce helped ease geopolitical tensions, and growing optimism over a potential US-India trade deal supported sentiment. Inflows from foreign institutional investors further contributed to the positive undertone. Even concerns around the July 9 U.S. tariff deadline took a backseat, as reports of a likely extension helped calm investor nerves. The Nifty traded below the 25,600 level. Private bank shares witnessed profit booking after advancing in the past two consecutive trading sessions. At 10:28 IST, the barometer index, the S&P BSE Sensex, declined 284.60 points or 0.33% to 83,778.85. The Nifty 50 index lost 82.05 points or 0.32% to 25,556.75. In the broader market, the S&P BSE Mid-Cap index rose 0.25% and the S&P BSE Small-Cap index jumped 0.62%. The market breadth was strong. On the BSE, 2,321 shares rose and 1,324 shares fell. A total of 222 shares were unchanged. The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, rallied 3.39% to 12.81. Economy: India's forex reserves dropped by USD 1.01 billion to USD 697.93 billion for the week ended June 20, the Reserve Bank of India said on Friday. For the week ended June 20, foreign currency assets, a major component of the reserves, dropped by USD 357 million to USD 589.06 billion, the data released on Friday showed. The gold reserves were down by USD 573 million to USD 85.74 billion during the week, the RBI said. The Special Drawing Rights (SDRs) declined by USD 85 million to USD 18.672 billion, the apex bank said. India's reserve position with the IMF also declined by USD 1 million to USD 4.45 billion in the reporting week, the apex bank data showed. Buzzing Index: The Nifty Private Bank index fell 0.31% to 28,417.85. The index rallied 1.34% in the past two consecutive trading sessions. Kotak Mahindra Bank (down 1.41%), HDFC Bank (down 0.60%), Axis Bank (down 0.52%) and ICICI Bank (down 0.50%) were the top losers. On the other hand, RBL Bank (up 3.73%), Bandhan Bank (up 2.35%) and Federal Bank (up 1.88%) edged higher. Stocks in Spotlight: Alembic Pharmaceuticals surged 8.40% after the company received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxorubicin Hydrochloride Liposome Injection. ITD Cementation India rallied 4.22% after the company secured an international marine contract worth $67.4 million (approximately Rs 580 crore) for jetty construction works related to the Ruwais LNG project in Abu Dhabi. Interarch Building Solutions rose 0.69%. The company announced that it has secured an order worth Rs 77 crore from Amara Raja Infra. Powered by Capital Market - Live
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Doxil Liposome Injection, of Baxter Healthcare Corporation. Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma. According to IQVIA, the estimated market size for Doxorubicin Hydrochloride Liposome Injection single-dose vials is $29 million for the 12 months ending March 2025. Alembic now has a cumulative total of 224 ANDA approvals from the USFDA, including 201 final approvals and 23 tentative approvals. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA. The company's consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24.Powered by Capital Market - Live
Alembic Pharmaceuticals announced that Viraj Save, Executive Vice President - Sales and Marketing has resigned from the said position and relieved w.e.f. 31 May 2025.Powered by Capital Market - Live
The inspection was conducted at the API-III facility from 17th March 2025 to 21st March 2025. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA. The company's consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24. Shares of Alembic Pharmaceuticals shed 0.78% to Rs 962.70 on the BSE.Powered by Capital Market - Live
Alembic Pharmaceuticals announced that the 15th Annual General Meeting(AGM) of the company will be held on 5 August 2025.Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 7.85%, vs industry avg of 10.1%
Over the last 5 years, market share decreased from 1.84% to 1.62%
Over the last 5 years, net income has grown at a yearly rate of -6.78%, vs industry avg of 20.04%